Core Viewpoint - Pharmaceutical stocks have declined again, with significant drops in various companies' stock prices, indicating a challenging market environment for the sector [1] Group 1: Stock Performance - Nocera Health (09969) fell by 11.37%, trading at HKD 14.73 [1] - Saint Noble Pharmaceuticals-B (02257) decreased by 11.05%, trading at HKD 13.36 [1] - Rongchang Biopharmaceutical (09995) dropped by 10.4%, trading at HKD 95.15 [1] - Gilead Sciences-B (01672) declined by 8.57%, trading at HKD 9.6 [1] - Viatris (01873) fell by 8.14%, trading at HKD 2.82 [1] Group 2: Investment Trends - According to CMB International, domestic investors have increased their holdings in pharmaceutical stocks through the Hong Kong Stock Connect since September, while foreign investment has slightly decreased since mid-year [1] - The overall trend of increasing investment in innovative drugs remains unchanged for both domestic and foreign investors [1] Group 3: Future Outlook - The ESMO conference is scheduled for mid to late October, with a recommendation to focus on companies like CanSino Biologics, Kelun-Biotech, Rongchang Biopharmaceutical, and Hengrui Medicine (600276) that are expected to release significant data [1] - The pharmaceutical sector in Hong Kong has shown relatively flat performance in September, but with the increase in industry catalysts (various academic conferences and favorable policies), the market is expected to rebound in October [1] Group 4: Market Analysis - Dongguan Securities reports that the pharmaceutical and biotechnology sector has consistently underperformed compared to the CSI 300 index, with some previously high-performing innovative drug companies experiencing corrections [1] - The medical research outsourcing sector has been strengthening due to improved expectations of U.S. interest rate cuts and better financing data, entering a performance vacuum period [1] - Future investment opportunities are suggested in innovative drugs and sectors with expected business development catalysts [1]

Core Viewpoint - The pharmaceutical sector is experiencing a decline, with significant drops in stock prices for various companies, while there is an increasing trend in domestic investment through the Hong Kong Stock Connect, indicating a mixed sentiment in the market [1]. Group 1: Stock Performance - Notable declines in pharmaceutical stocks include: - Innovent Biologics (09969) down 11.37% to HKD 14.73 - Sanofi (02257) down 11.05% to HKD 13.36 - Rongchang Biopharmaceutical (09995) down 10.4% to HKD 95.15 - Galenica (01672) down 8.57% to HKD 9.6 - Viatris (01873) down 8.14% to HKD 2.82 [1]. Group 2: Investment Trends - According to CICC, since September, the proportion of domestic investors holding pharmaceutical stocks through the Hong Kong Stock Connect has been increasing, while foreign investment has slightly decreased since mid-year [1]. - Despite the decline, the overall trend of increasing investment in innovative drugs remains unchanged [1]. Group 3: Future Outlook - The upcoming ESMO conference in mid-October is highlighted as a key event, with recommendations to focus on companies like CanSino Biologics, Kelun-Biotech, Rongchang Biopharmaceutical, and Heng Rui Medicine, which are expected to release significant data [1]. - Dongguan Securities reports that the pharmaceutical and biotechnology sector has underperformed compared to the CSI 300 index, with some previously high-performing innovative drug companies experiencing corrections [1]. - The medical research outsourcing sector is showing strength due to improved financing data and expectations of catalysts in innovative drugs, suggesting potential investment opportunities [1].

Market Performance - The Hong Kong stock market continued its decline, with notable drops in several biotech companies [1] - Innovent Biologics (09969) fell by 11.19%, closing at 14.760, with a market capitalization of 26.021 billion and a year-to-date increase of 141.18% [2] - Rongchang Biologics (09995) decreased by 10.22%, with a latest price of 95.350 and a total market value of 53.74 billion, reflecting a year-to-date increase of 562.15% [2] - WuXi AppTec (02268) and WuXi Biologics (02269) experienced declines of 5.68% and 5.32%, respectively, with market caps of 89.818 billion and 1585.28 billion [2] - Other companies such as Fuhong Hanlin (02696) and Kelun-Biotech (06990) also saw declines of over 4% [1][2] Company Highlights - Innovent Biologics has shown a significant year-to-date performance increase of 141.18% despite the recent drop [2] - Rongchang Biologics has the highest year-to-date increase among the listed companies at 562.15% [2] - WuXi Biologics and WuXi AppTec have maintained strong year-to-date increases of 120.84% and 138.50%, respectively [2] - Fuhong Hanlin and Kelun-Biotech also reported substantial year-to-date increases of 205.49% and 199.33% [2]

Group 1 - The core viewpoint of the report highlights that international gold prices have surpassed the $4000 per ounce mark, impacting various sectors positively, particularly the metals sector [2][4][6] - The Hong Kong stock market showed mixed results with the Hang Seng Index declining by 0.29%, while the Hang Seng Tech Index fell by 0.66%, indicating volatility in the market [2][3] - The report notes significant inflows from northbound funds, with a net inflow of HKD 30.43 billion into Hong Kong stocks, suggesting strong investor interest [2][3] Group 2 - The report provides insights into the software and internet industry, indicating a robust domestic tourism performance during the National Day holiday, with total tourism revenue reaching CNY 809 billion and a year-on-year increase of 15% in revenue per capita [7][8] - The report anticipates a stable growth rate of 10% for the overall tourism market in 2025, with expectations of a rebound in average spending per person in the second half of the year [7][10] - Online travel agencies (OTAs) like Ctrip and Qunar have shown strong performance, with significant increases in outbound travel orders and hotel bookings, reflecting a positive trend in consumer behavior [9][10]

Core Viewpoint - The Hong Kong biopharmaceutical stocks continued to decline, with significant drops in several key companies, indicating a bearish trend in the sector [1]. Group 1: Stock Performance - Innovent Biologics (09969) experienced a decline of 11.19%, with a latest price of 14.760 and a total market capitalization of 26.021 billion, despite a year-to-date increase of 141.18% [2]. - Rongchang Biologics (09995) fell by 10.22%, with a latest price of 95.350 and a market cap of 53.747 billion, showing a remarkable year-to-date increase of 562.15% [2]. - WuXi AppTec (02268) saw a decrease of 5.68%, with a latest price of 73.100 and a market cap of 89.818 billion, maintaining a year-to-date increase of 138.50% [2]. - WuXi Biologics (02269) dropped by 5.32%, with a latest price of 38.780 and a market cap of 158.528 billion, reflecting a year-to-date increase of 120.84% [2]. - Fuhong Hanlin (02696) declined by 4.42%, with a latest price of 72.400 and a market cap of 39.349 billion, showing a year-to-date increase of 205.49% [2]. - Kelun-Biotech (06990) decreased by 4.25%, with a latest price of 488.800 and a market cap of 113.981 billion, with a year-to-date increase of 199.33% [2]. - WuXi AppTec (02359) fell by 4.19%, with a latest price of 114.400 and a market cap of 339.275 billion, reflecting a year-to-date increase of 109.21% [2]. - Gendicine (09688) saw a decrease of 2.83%, with a latest price of 25.440 and a market cap of 28.432 billion, with a year-to-date increase of 21.72% [2]. - CanSino Biologics (09926) declined by 2.05%, with a latest price of 128.800 and a market cap of 118.643 billion, reflecting a year-to-date increase of 112.19% [2]. - Junshi Biosciences (01877) fell by 2.02%, with a latest price of 29.100 and a market cap of 29.877 billion, showing a year-to-date increase of 151.30% [2].

Core Viewpoint - The Hong Kong stock market for innovative drug concept stocks continues to decline, with significant drops in several companies' stock prices [1] Company Performance - Innovent Biologics (诺诚健华) and Rongchang Biopharmaceutical (荣昌生物) both experienced declines exceeding 10% [1] - Genscript Biotech (歌礼制药-B) saw a drop of over 8% [1] - Other companies such as Kanglong Chemical (康龙化成) and WuXi Biologics (药明生物) also reported notable declines in their stock prices [1]

Market Performance - The Hang Seng Healthcare Index decreased by 1.16% as of October 10, 2025, with mixed performance among constituent stocks [2] - The Hang Seng Medical ETF (513060) fell by 1.24%, with a latest price of 0.72 yuan, but has seen a cumulative increase of 25.95% over the past three months [2] - The CSI Pharmaceutical 50 Index dropped by 1.58%, with the Medical 50 ETF (159838) down by 1.50%, latest price at 0.66 yuan, and a 0.91% increase over the past two weeks [6] Key Events - Novo Nordisk announced the acquisition of Akero Therapeutics for up to $5.2 billion, enhancing its position in the metabolic disease sector, particularly in non-alcoholic fatty liver disease, obesity, and diabetes [6] - Wuhan East Lake High-tech Zone introduced measures to support the development of brain-computer interface technology, aiming to attract research institutions and companies to accelerate innovation in high-end medical devices and neuroengineering [6] - Changfeng Pharmaceutical successfully listed on the Hong Kong Stock Exchange, indicating strong market interest in respiratory drugs and inhalation delivery technology [7] Institutional Insights - The global pharmaceutical sector continues to exhibit a structural trend of "innovation focus + policy catalysis," with increased attention on metabolic disease pipelines following Novo Nordisk's acquisition [7] - The implementation of brain-computer interface policies highlights national strategic support for cutting-edge medical technology, potentially boosting innovation in medical devices and neuroregulation [7] - The listing of Changfeng Pharmaceutical reflects a recovery trend for new pharmaceutical stocks in Hong Kong, with a shift in funding focus from traditional pharmaceuticals to innovative technologies and differentiated pipelines [7] Related ETFs - The Hang Seng Medical ETF (513060) tracks the Hang Seng Healthcare Index, covering core assets in Hong Kong's healthcare sector [8] - The Hong Kong Innovative Drug Selection ETF (520690) closely follows the Hang Seng Hong Kong Stock Connect Innovative Drug Selection Index, focusing on leading innovative drug companies [9] - The Medical 50 ETF (159838) tracks the CSI Pharmaceutical 50 Index, encompassing major players in the pharmaceutical and healthcare sectors [9]

Group 1: Hong Kong Stocks - Nocera Biotech (09969) fell over 8% after announcing a licensing collaboration with Zenas for three self-immune pipeline products [1] - Pop Mart (09992) rose over 2% as new products sold out immediately, with Morgan Stanley optimistic about the company's sales momentum [1] - Bluec (00325) increased over 8% after launching new "building block cars" and "building block figures" at the WF2025 exhibition [1] - Huaxin Cement (06655) rose over 7% after announcing a name change to "Huaxin Building Materials" and a restricted stock incentive plan [1] - Mixue Group (02097) gained over 5% after announcing an investment of nearly 300 million in the fresh beer industry, potentially opening up long-term growth opportunities [1] - CATL (03750) dropped nearly 6% as the cornerstone lock-up period is set to expire on the 19th of next month, with both Morgan Stanley and others downgrading the company's H-share rating [1] - Dazhong Public Utilities (01635) rose over 9%, stating that its operations are normal and previously mentioned its stake in Shenzhen Capital Group [1] - Jinli Permanent Magnet (06680) increased nearly 1%, forecasting a year-on-year increase of 157%-179% in net profit attributable to shareholders for the first three quarters [1] Group 2: Gold Stocks - Gold stocks opened lower collectively, with China Gold International (02099) down over 7%, Zijin Mining International (02259) down over 1%, Shandong Gold (01787) down over 6%, and Chifeng Jilong Gold Mining (06693) down over 6% due to easing geopolitical tensions leading to a pullback in precious metals [2] Group 3: US Stocks - AMBO Education (AMBO.US) surged 61.06% after announcing the launch of a real-time translation platform, WeSpeak, for enterprises [3] - CenturyLink (VNET.US) fell 3.13% as Goldman Sachs included it in a "strong buy" list for the Asia-Pacific region [3] - UiPath (PATH.US) rose 18.81% after announcing multiple collaborations with major tech companies like NVIDIA, OpenAI, Google, Microsoft, and Snowflake [3] - Tuniu (TOUR.US) decreased by 0.51%, despite a double-digit increase in user travel during this year's "Double Festival" holiday compared to last year [3] - Tesla (TSLA.US) fell 0.72% after reports that production of its humanoid robot, Optimus, has been paused [3] - Toyota (TM.US) dropped 2.97% after a recall of over 390,000 vehicles in the US due to software errors [3] - Lloyds Bank (LYG.US) decreased by 3.67% as it may need to increase provisions following a compensation plan for mis-sold auto loans [3] - Ferrari (RACE.US) fell 14.99%, reaching a six-month low as long-term profit guidance fell below expectations [4] - TSMC (TSM.US) decreased by 1.52%, projecting a consolidated revenue of approximately NT$330.98 billion for September 2025, a 1.4% decrease quarter-on-quarter but a 31.4% increase year-on-year [4] - PepsiCo (PEP.US) rose 4.23% with Q3 net revenue increasing by 2.7% to $23.94 billion, and core EPS of $2.29, both exceeding expectations [4]

Market Overview - The Hang Seng Index fell by 1.14%, down 304 points, closing at 26,447 points, while the Hang Seng Tech Index dropped by 2.45% [1] - The trading volume in the Hong Kong stock market reached HKD 180.3 billion in the morning session [1] Tea Beverage Sector - Tea beverage stocks performed strongly, with significant sales during the holiday period; companies are accelerating their overseas expansion [1] - Gu Ming (01364) rose by 13.23%, Nayuki (02150) increased by 7.26%, and Mixue Group (02097) gained 5.98% [1] Insurance Sector - Domestic insurance stocks collectively rose, driven by the return of dividend-type health insurance after 22 years, enhancing the attractiveness of insurance products [1] - New China Life Insurance (01336) increased by 3.11%, China Pacific Insurance (02601) rose by 3.02%, and China Life Insurance (02628) also gained 3.02% [1] Retail Sector - Xiao Cai Yuan (00999) saw a rise of over 9%, with impressive operational data during the National Day holiday, reporting a 21% year-on-year increase in customer traffic across its stores [1] New Product Launches - Blokku (00325) surged over 11% after launching new product lines "Building Cars" and "Building People" at the WF2025 exhibition [1] Construction Materials Sector - Jinju Group (02009) rose by over 5%, actively promoting new building materials and securing significant overseas project contracts [1] Graphite Sector - China Graphite (02237) surged by over 24% following export controls imposed by two departments on lithium battery and artificial graphite anode materials [1] Semiconductor Sector - Chip stocks continued to decline, with several brokerages adjusting the margin financing rates for SMIC, leading to a 5.6% drop in SMIC (00981) and a 4% decline in Hua Hong Semiconductor (01347) [1][3] Biotechnology Sector - Innovent Biologics (09969) fell over 9% after announcing a licensing collaboration with Zenas for three self-immune pipeline products [2] Battery Sector - Contemporary Amperex Technology Co. (03750) dropped over 7% as the cornerstone lock-up period is set to expire on the 19th of next month, with major brokerages downgrading the company's H-share rating [3]

Core Insights - The collaboration between Innovent Biologics and Zenas for three self-immune pipeline products marks a significant milestone in the internationalization of the drug Orelabrutinib and sets a new record for small molecule transactions in China's self-immune field, with a total potential transaction value exceeding $2 billion [1] - The development of the first-class new drug HH-003 (Libevev) by Huahui Anjian, targeting chronic hepatitis D, is expected to receive approval for market launch around the first quarter of 2026, representing a major milestone in the company's growth [2][3] Company Developments - Huahui Anjian has been developing HH-003 since its inception, with significant funding rounds supporting its clinical trials, including a recent A++ round financing and breakthrough therapy designation from the FDA for treating chronic hepatitis D [3][4] - The drug HH-003 has shown promising results in clinical trials, demonstrating good safety and antiviral activity, with a notable decrease in HBV DNA and hepatitis B surface antigen levels observed in patients [3][4] Industry Context - The Zhongguancun Life Science Park, where both Innovent Biologics and Huahui Anjian are based, is a key area for biotechnology innovation in Beijing, having produced significant drugs like Orelabrutinib and Zebutinib [1][5] - The park is recognized for its comprehensive industry chain, facilitating the transition from laboratory research to clinical application, thus fostering a competitive pharmaceutical health industry [10] Product Pipeline and Market Potential - Innovent Biologics has developed Orelabrutinib, a BTK inhibitor that has been approved in China and Singapore, with plans for further clinical trials targeting multiple sclerosis [6][7] - The company is also advancing its pipeline with a new generation TRK inhibitor, demonstrating a strategic focus on expanding its product offerings in oncology and autoimmune diseases [7][8] Competitive Landscape - The competitive landscape for BTK inhibitors in China includes several products, with Orelabrutinib positioned to capture market share due to its rapid development and broad application potential [6] - WanTai Biologics, another company in the park, is expanding its vaccine pipeline, including the world's first marketed hepatitis E vaccine, showcasing the diverse innovation occurring within the Zhongguancun Life Science Park [9][10]